Common adverse reactions (≥10%) across all cohorts in GEOMETRY mono-12,3
TABRECTA® (capmatinib) tablets (N=373) | |||
COMMON ADVERSE REACTIONS | ALL GRADES (%) | GRADE 3 (%) | GRADE 4 (%) |
General disorders and administration-site conditions | |||
Edemaa | 59 | 13 | - |
Musculoskeletal painb | 40 | 4.3 | - |
Fatiguec | 34 | 8 | - |
Pyrexiad | 14 | 0.8 | - |
Weight decreased | 11 | 0.5 | - |
Gastrointestinal disorders | |||
Nausea | 46 | 2.4 | - |
Vomiting | 28 | 2.4 | - |
Constipation | 19 | 0.8 | - |
Diarrhea | 19 | 0.5 | - |
Respiratory, thoracic, and mediastinal disorders | |||
Dyspnea | 25 | 7* | 0.5 |
Coughe | 21 | 0.5 | - |
Pneumoniaf | 13 | 6* | 0.5 |
Metabolism and nutrition disorders | |||
Decreased appetite | 21 | 1.1 | - |
Skin and subcutaneous tissue disorders | |||
Rashg | 13 | 0.5 | - |
Nervous system disorders | |||
Dizzinessh | 13 | 0.5 | - |
aEdema includes edema peripheral, generalized edema, face edema, edema, localized edema, edema genital, eyelid edema, peripheral swelling, scrotal edema, and penile edema.
bMusculoskeletal pain includes arthralgia, back pain, bone pain, musculoskeletal chest pain, musculoskeletal pain, myalgia, neck pain, noncardiac chest pain, pain in extremity, pain in jaw, spinal pain.
cFatigue includes fatigue and asthenia.
dPyrexia includes pyrexia and body temperature increased.
eCough includes cough, upper airway cough syndrome, and productive cough.
fPneumonia includes pneumonia aspiration, pneumonia, pneumonia influenzal, pneumonia bacterial, lower respiratory tract infection, and lung abscess.
gRash includes rash, dermatitis acneiform, rash maculo-papular, eczema, erythema multiforme, rash macular, dermatitis, rash erythematous, rash pustular, dermatitis bullous, and rash vesicular.
hDizziness includes dizziness, vertigo, and vertigo positional.
*Includes both grade 3 and 4.
The majority of patients who reported adverse reactions (ARs) remained on TABRECTA® (capmatinib) tablets.2
Dose reductions due to ARs occurred in 26% of patients, and dose interruptions due to ARs occurred in 57% of patients2
Sixty-five patients (17%) treated with TABRECTA® (capmatinib) tablets discontinued therapy due to ARs2,3
The most frequent ARs (≥1%) leading to permanent discontinuation of TABRECTA were ILD/pneumonitis (2.4%), edema (2.4%), fatigue (1.3%), and pneumonia (1.1%)
Fatal ARs occurred in 0.5% of patients who received TABRECTA, including pneumonitis (0.3%) and death, not otherwise specified (0.3%).2
Clinically relevant ARs occurring in <10% of patients treated with TABRECTA® (capmatinib) tablets included pruritus (including allergic pruritus), ILD/pneumonitis, cellulitis, acute kidney injury (including renal failure), urticaria, and acute pancreatitis.2
Serious hypersensitivity reactions and thrombocytopenia occurred in patients treated with TABRECTA® (capmatinib) tablets in clinical trials other than GEOMETRY mono-1.2